anticorpo monoclonal quimérico, composição farmacêutica, e, uso de um anticorpo monoclonal

• Main Authors: Lourdes Tatiana Roque Navarro, Josefa Lombardero Valladares, Cristina M. Mateo de Acosta Del Río, Alejandro López Requena
• Format: Patent
• Language: Portuguese
• Published: 14.11.2017
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

anticorpo monoclonal quimérico, linhagem celular, composição farmacêutica, e, uso de um anticorpo monoclonal a presente invenção refere-se à obtenção de anticorpos modificados por engenharia genética a partir do anticorpo monoclonal murino p3 (acm p3), produzido pelo hibridoma depositado segundo o tratado de budapeste sob o número ecacc 94113026 e de seu anti-idiotipo 1e10 (acmai 1e10) produzido pelo hibridoma ecacc 97112901, com o objetivo de se obterem anticorpos com as mesmas propriedades de reconhecimento dos originais mas que sejam menos imunógenos que estes. os anticorpos quiméricos, contem os domínios variáveis da imunoglobulina murina e as regiões constantes da imunoglobulina humana; e os humanizados, além de conterem as regiões constantes da imunoglobulina humana, estão modificados na região das estruturas (frs) murinas e em particular naquelas zonas que podem resultar em um sítio antigênico para as células 1, acarretando que algumas posições das frs são humanizadas. estes anticorpos podem ser utilizados em diagnóstico e em terapia de diferentes tipos de tumores. Composition (A) for immunotherapy of tumors that overexpress gangliosides (I) comprises at least two of: (a) idiotypic vaccine containing anti-ganglioside antibody (Ab1); (b) idiotypic vaccine containing anti-idiotypic antibody (Ab2) specifically directed against a monoclonal anti-ganglioside antibody; and (c) vaccine containing (I). ACTIVITY : Cytostatic; Immunostimulant. Male mice were immunized subcutaneously with 4 doses of the 1E10 anti-idiotypic antibody (50 Microg, days 0, 14, 28 and 42) on alumina gel, and intramuscularly with the ganglioside GM3-VSSP (120 Microg, days 7, 21, 35 and 49) on Montanide ISA51. On day 63, the animals were inoculated subcutaneously with 10 4> B16 murine tumor cells. Treatment was 1E10 alone did not slow tumor growth (tumor size after 31 days, about 12 units); GM3-VSSP alone did slow growth (size about 4.5 units) but the combination of both was most effective (size about 1.5 units). MECHANISM OF ACTION : Induction of a specific immune response, both humoral and cellular; Vaccine.